In late March, Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. announced 10,000 layoffs across ...

Christine Pascual’s phone started buzzing while she was at work in a hair salon with messages saying former Philippine ...

As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency ...

The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...

Aldeyra received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the NDA ...

The FDA has set a goal date of Aug. 27, 2025. If approved, the therapy would be branded as Lytenava and be the first ...

On this "Face the Nation with Margaret Brennan" broadcast, moderated by Margaret Brennan: U.S. trade representative Jamieson ...

The FDA confirmed that the resubmission was a complete, Class 1 response to the previous action letter issued on August 16, 2024, which granted tentative approval of YUTREPIA for both PAH and PH-ILD.

In this week’s edition of InnovationRx, we look at Trump's massive health agency layoffs, Palantir’s trade secret lawsuit, Gather Health’s new primary care model, Airna’s $155 million deal, and more.

Following the dramatic late-night resignation of Peter Marks last Friday, Steele, a senior advisor to the division, takes the ...

Despite the current hurdle, Aldeyra reported a solid financial standing with $101 million in cash, cash equivalents, and marketable securities as of December 31, 2024. The company also noted that a ...

In November 2023, the FDA issued a Complete Response Letter to the initial NDA stating ... mid-year 2025,” stated Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra ...